Compare iShares Core S&P 500 ETF (IVV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares Core S&P 500 ETFTrade

Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Core S&P 500 ETF trades at $752.46, while Zimmer Biomet Holdings Inc trades at $89.63 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

	IVV	ZBH
Sector	Broad Market / Factor	Health
52-Week High	$763.10	$107.71
52-Week Low	$624.65	$79.58
Market Cap	—	$17.36B
Enterprise Value	—	$24.40B
Dividend Yield	—	1.07%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $745.67, down 0.14% with a bearish technical signal from moving averages. The fund remains heavily weighted toward technology stocks, with recent news highlighting concentration risks and debates over valuation. A dividend of $2.00 is scheduled for June 2026, providing income amid market volatility.

Outlook is cautious due to technical weakness and high tech exposure, though long-term growth prospects from AI and earnings strength offer potential. Key risks include market concentration, valuation concerns, and macroeconomic shifts impacting broad index performance.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.

ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IVV

Invesco S&P 500 Equal Weight Consumer Discretionary ETF seen as a Hold, likely underperforming IVV again.Seeking Alpha · 2 days agoNeutral BlackRock's MAXJ ETF offers S&P 500 returns with downside protection but caps gains at 10.6%.24/7 Wall Street · 3 days agoNeutral SPY ETF charges higher fees than its cheaper sibling SPYM with identical S&P 500 exposure.24/7 Wall Street · 3 days agoBearish View details →

ZBH

View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.